Neuroblastoma, a highly aggressive childhood cancer, presents a high risk of relapse, making long-term disease control a significant challenge. A groundbreaking study published in Nature Medicine has demonstrated that GD2-directed CAR-T cell therapy can induce durable remissions, with one patient remaining cancer-free for over 18 years, the longest reported remission for a solid tumor treated with CAR-T cells. Between 2004 and 2009, 19 children were infused with CAR-T cells targeting GD2, a protein expressed in neuroblastoma cells, as part of a phase I clinical trial. Despite lacking modern co-stimulatory molecules, these first-generation CAR-T cells persisted for over five years in some patients. Among patients with active disease, 3 achieved complete responses, with 2 maintaining long-term remissions of 8+ and 18+ years, respectively. Immune profiling of long-term survivors revealed that CAR-T cells exhibited a mix of effector and memory-like properties, suggesting a key role in extended therapeutic effects. This study indicates the safety and durability of GD2 CAR-T therapy in neuroblastoma and paves the way for improved CAR-T strategies targeting solid tumors.
